Sanacor

Sanacor’s first mission is to reverse diabetic cardiovascular disease. The company’s scientific foundation is based on nearly two decades of Widlansky Labs research and has received funding from the NIH and AHA. Cardiovascular disease is the #1 killer of diabetics. By 2045, over 500 million people will die from diabetic cardiovascular disease with an annual cost of care of $350 billion, and no effective treatments. The Widlansky lab discovered the underlying cause and developed a compound that safely reverses the disease by blocking FIS1 in human models. Sanacor also has begun early work to explore other areas where FIS1 is implicated such as diabetic kidney and eye disease, neurodegeneration, oncology and rare mitochondrial diseases.

所属行业

生物技术研究

规模

2-10 人

总部

Milwaukee，WI

类型

私人持股

创立

2023